Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Fish and Richardson
Express Scripts
Cerilliant
Harvard Business School
US Army
Johnson and Johnson
McKesson
Colorcon
Covington

Generated: January 16, 2018

DrugPatentWatch Database Preview

Eprosartan mesylate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for eprosartan mesylate and what is the scope of eprosartan mesylate patent protection?

Eprosartan mesylate
is the generic ingredient in three branded drugs marketed by Mylan Pharms Inc and Abbvie, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There are eleven drug master file entries for eprosartan mesylate. One supplier is listed for this compound.
Pharmacology for eprosartan mesylate

US Patents and Regulatory Information for eprosartan mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-002 Nov 1, 2001 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-004 Dec 22, 1997 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-006 May 27, 1999 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Pharms Inc EPROSARTAN MESYLATE eprosartan mesylate TABLET;ORAL 202012-002 Nov 16, 2011 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-001 Nov 1, 2001 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-005 Dec 22, 1997 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Pharms Inc EPROSARTAN MESYLATE eprosartan mesylate TABLET;ORAL 202012-001 Nov 16, 2011 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for eprosartan mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-006 May 27, 1999 ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-004 Dec 22, 1997 ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-004 Dec 22, 1997 ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-006 May 27, 1999 ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-005 Dec 22, 1997 ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-005 Dec 22, 1997 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
McKinsey
Teva
US Army
Cipla
McKesson
Moodys
Johnson and Johnson
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot